Session

IBD: Clinical trials III

HIGH DOSE ORAL THIAMINE REDUCES CHRONIC FATIGUE IN PATIENTS WITH QUIESCENT INFLAMMATORY BOWEL DISEASE: A RANDOMISED DOUBLE BLINDED CROSSOVER TRIAL
HIGH DOSE ORAL THIAMINE REDUCES CHRONIC FATIGUE IN PATIENTS WITH QUIESCENT INFLAMMATORY BOWEL DISEASE: A RANDOMISED DOUBLE BLINDED CROSSOVER TRIAL

IBD: Clinical trials III  et al.

PATTERN OF BIOLOGICAL USE AND TREATMENT OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES - A DANISH NATIONWIDE COHORT STUDY
PATTERN OF BIOLOGICAL USE AND TREATMENT OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES - A DANISH NATIONWIDE COHORT STUDY

IBD: Clinical trials III  et al.

COBITOLIMOD FOR MODERATE-TO-SEVERE LEFT-SIDED ULCERATIVE COLITIS (CONDUCT): A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL
COBITOLIMOD FOR MODERATE-TO-SEVERE LEFT-SIDED ULCERATIVE COLITIS (CONDUCT): A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL

IBD: Clinical trials III  et al.

USTEKINUMAB IS MORE EFFECTIVE THAN AZATHIOPRINE TO PREVENT ENDOSCOPIC POSTOPERATIVE RECURRENCE IN CROHN´S DISEASE
USTEKINUMAB IS MORE EFFECTIVE THAN AZATHIOPRINE TO PREVENT ENDOSCOPIC POSTOPERATIVE RECURRENCE IN CROHN´S DISEASE

IBD: Clinical trials III  et al.

LONG-TERM EVOLUTION AFTER ANTI-TNF DRUG DISCONTINUATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
LONG-TERM EVOLUTION AFTER ANTI-TNF DRUG DISCONTINUATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD: Clinical trials III  et al.

Item 1 - 5 / 5
1